DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
DNA topoisomerase IIß inhibition blocks DNA end resection and synergizes with PARPi in BRCA1-deficient models
DNA end resection is a critical step that governs how a broken chromosome will be repaired. As such, it is heavily regulated by multiple cellular signals and processes. Alterations in the regulation of DNA end resection have consequences for cell survival upon exposure to cytotoxic agents, including those used during cancer chemotherapy. Here, we identified several small molecules that affect the process of DNA end resection. Among them, we focus on determining the mode of action of merbarone, a DNA topoisomerase II inhibitor. We uncover a role of the topoisomerase IIβ isoform in the full processing of DNA breaks. Moreover, we show that the effect of merbarone is affected by the formation of G4 quadruplexes and that BRCA1-deficient cancer cells are sensitive to merbarone. Strikingly, this sensitivity can be partially suppressed in cell lines expressing hypomorphic versions of BRCA1 lacking exon 11, a hypomorph that has been linked to PARPi-resistance. Using cellular models, we show that PARPi- and merbarone-resistant BRCA1 exon 11 mutant cells, but not wildtype BRCA1 cells, are sensitive to the combination of both drugs. Finally, we show that combination of merbarone and the PARPi olaparib has a mild antitumor effect in a PARPi-resistant PDX model bearing a BRCA1 exon 11 mutation., This work was funded by the R+D+I grants SAF2013-43255-P, SAF2016-74855-P, PID2019-104195G and PID2022-136791NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE to P.H., and grants PID2022-140603NB-I00 funded by MICIU/AEI/10.13039/501100011033/ FEDER/UE and the Ideas Semilla Project IDEAS222767JIME from the Asociación Española Contra el Cáncer (AECC) to S.J and the SINERGIA project SNRGS247052PRAD from AECC to RP-C. RC-D was funded with an FPI fellowship from the Spanish Ministry of Economy and Competitivity. RP-C was funded with an FPU fellowship from the Spanish Ministry of Education and a Postdoctoral Fellowship from the Asociación Española Contra el Cáncer (AECC). AC-G was supported by the Government of Mexico with a fellowship of the CONACYT. CABIMER is supported by the Regional Government of Andalucía (Junta de Andalucía). V.S. received funds from the Instituto de Salud Carlos III (ISCIII), an initiative of the Spanish Ministry of Economy and Innovation partially supported by European Regional Development FEDER Funds (PI20/00892 and CPII19/00033). AH-R received funding from Generalitat de Catalunya (PERIS SLT017/20/000081).
P. Huertas and R. Prados-Carvajal disclose non-financial support from AstraZeneca. Additionally, V. Serra reports research grants from AstraZeneca and personal fees and/or nonfinancial support from AstraZeneca and GSK., Peer reviewed
Proyecto:
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 SAF2013-43255-P
,
MINECO / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 SAF2016-74855-P
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2019-104195GB-I00
,
AEI PID2022-136791NB-I00
,
AEI PID2022-140603NB-I00
DOI: http://hdl.handle.net/10261/400250, https://api.elsevier.com/content/abstract/scopus_id/105009497689
HANDLE: http://hdl.handle.net/10261/400250, https://api.elsevier.com/content/abstract/scopus_id/105009497689